Target RWE Showcases Innovative Research at ISPE 2025 Conference in Washington, D.C. Target RWE is set to present key research findings at the ISPE 2025 Annual Conference in Washington, D.C., focusing on causal inference and data-agnostic methods.

Target RWE Showcases Innovative Research at ISPE 2025 Conference in Washington, D.C. #USA #Washington,_D.C. #Target_RWE #causal_inference #ISPE_2025

Target RWE Unveils Innovative Causal Inference Techniques in Latest Publications Target RWE has published two groundbreaking papers that enhance causal inference methods in real-world evidence, advancing healthcare decision-making and regulatory processes.

Target RWE Unveils Innovative Causal Inference Techniques in Latest Publications #United_States #Target_RWE #Durham,_N.C. #Real-World_Evidence #causal_inference

Target RWE Shines a Spotlight on Liver Disease Research at EASL 2025 Congress At EASL 2025, Target RWE shared pivotal findings in liver disease research, focusing on MASH, HCC, and PBC treatment advancements.

Target RWE Shines a Spotlight on Liver Disease Research at EASL 2025 Congress #None #Target_RWE #Liver_Disease #Amsterdam #EASL_2025

Advancements in Patient-Centric Data Capture Propel Target RWE's Innovative Dermatology Research Target RWE has revealed significant improvements in their dermatology studies through a patient-centric approach, covering various skin conditions.

Advancements in Patient-Centric Data Capture Propel Target RWE's Innovative Dermatology Research #United_States #Durham #Target_RWE #Real_World_Evidence #Dermatology_Study

Exploring New Insights from Target RWE on NASH-CHECK and Patient Outcomes in MASLD At The Liver Meeting 2024, Target RWE shared key findings about NASH-CHECK's patient-reported outcomes for MASLD, highlighting vital differences in cirrhosis effects.

Exploring New Insights from Target RWE on NASH-CHECK and Patient Outcomes in MASLD #United_States #Durham #Target_RWE #MASLD #NASH-CHECK

Target RWE Unveils GLP-1 Receptor Agonists Benefits at The Liver Meeting 2024 Target RWE presents groundbreaking research on GLP-1 receptor agonists' effectiveness in patients with MASLD at The Liver Meeting 2024, showcasing potential for improved outcomes.

Target RWE Unveils GLP-1 Receptor Agonists Benefits at The Liver Meeting 2024 #United_States #San_Diego #Target_RWE #GLP-1_Agonists #MASLD

Latest Insights from ACG 2024: Target RWE Updates on MASH and EGIDs Research in Liver Disease Target RWE shared significant findings at ACG 2024 about metabolic dysfunction-associated steatohepatitis and eosinophilic gastrointestinal diseases, enhancing patient treatment insights.

Latest Insights from ACG 2024: Target RWE Updates on MASH and EGIDs Research in Liver Disease #None #Target_RWE #MASH #EGIDs #Durham,_N.C.

Prominent Research by Target RWE Validates New Liver Disease Terms for Pediatric Patients Target RWE has unveiled groundbreaking research confirming new terminology for fatty liver disease in children, showcasing significant diagnostic concordance.

Prominent Research by Target RWE Validates New Liver Disease Terms for Pediatric Patients #United_States #Target_RWE #Liver_Disease #Pediatric_Health #Durham,_NC